Mycobacterium tuberculosis epitope-specific interferon-gamma production in healthy Brazilians reactive and non-reactive to tuberculin skin test by Maciel da Silva, Bosco Christiano et al.
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 109(8): 999-1004, December 2014 999
online | memorias.ioc.fiocruz.br
Mycobacterium tuberculosis epitope-specific interferon-g production 
in healthy Brazilians reactive and non-reactive to tuberculin skin test
Bosco Christiano Maciel da Silva1, Maria Fernanda Rios Grassi2,3, Raimundo Coutinho2,  
Rita Elizabeth Moreira Mascarenhas2,3, Viviana Nilla Olavarria2,3, Adriana Coutinho-Borgo1,4,  
Jorge Kalil1,4,5, Edecio Cunha-Neto1,4,5, Simone Gonçalves Fonseca1,5/+
1Laboratório de Imunologia, Instituto do Coração 4Divisão de Imunologia Clínica e Alergia, Departamento de Medicina,  
Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil 2Laboratório Avançado de Saúde Pública,  
Fundação Oswaldo Cruz, Salvador, BA, Brasil 3Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brasil  
5Instituto de Investigação em Imunologia, São Paulo, SP, Brasil
The interferon (IFN)-γ response to peptides can be a useful diagnostic marker of Mycobacterium tuberculosis 
(MTB) latent infection. We identified promiscuous and potentially protective CD4+ T-cell epitopes from the most 
conserved regions of MTB antigenic proteins by scanning the MTB antigenic proteins GroEL2, phosphate-binding 
protein 1 precursor and 19 kDa antigen with the TEPITOPE algorithm. Seven peptide sequences predicted to bind 
to multiple human leukocyte antigen (HLA)-DR molecules were synthesised and tested with IFN-γ enzyme-linked 
immunospot (ELISPOT) assays using peripheral blood mononuclear cells (PBMCs) from 16 Mantoux tuberculin 
skin test (TST)-positive and 16 TST-negative healthy donors. Eighty-eight percent of TST-positive donors responded 
to at least one of the peptides, compared to 25% of TST-negative donors. Each individual peptide induced IFN-γ 
production by PBMCs from at least 31% of the TST-positive donors. The magnitude of the response against all pep-
tides was 182 ± 230 x 106 IFN-γ  spot forming cells (SFC) among TST-positive donors and 36 ± 62 x 106 SFC among 
TST-negative donors (p = 0.007). The response to GroEL2 (463-477) was only observed in the TST-positive group. 
This combination of novel MTB CD4 T-cell epitopes should be tested in a larger cohort of individuals with latent 
tuberculosis (TB) to evaluate its potential to diagnose latent TB and it may be included in ELISPOT-based IFN-γ 
assays to identify individuals with this condition.
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Infection by Mycobacterium tuberculosis (MTB) re-
mains a major public health problem in the world. In this 
respect, tuberculosis (TB) is the second cause of death af-
ter human immunodeficiency virus (HIV) infection and 
is the most common cause of death of people infected 
with HIV (Corbett et al. 2003, Blanc & Martinez 2007).
Most MTB-infected individuals remain asymp-
tomatic, with a small proportion of them eventually 
progressing to active TB disease. Therefore, they may 
become a reservoir of Mycobacterium and this may con-
stitute an obstacle to its eradication. The most common 
manifestation of TB is a chronic pulmonary disease and 
immunocompromised individuals are the most prone to 
developing symptomatic disease (Girardi et al. 2000, 
Stewart et al. 2003).
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The diagnosis of latent MTB infection remains a chal-
lenge. The tuberculin skin test (TST), also known as the 
purified protein derivative (PPD) skin test, is still large-
ly employed as a diagnostic tool, but it has shown low 
specificity, as it often displays antigenic cross-reactivity 
with unrelated microorganisms (Dinnes et al. 2007). The 
tests that measure interferon (IFN)-γ production, IFN-γ 
release assays (IGRA), were developed to detect latent 
TB and are based upon the detection of IFN-γ produced 
specifically from peptides identified during infection 
with MTB; they are considered to be more specific than 
TST for the diagnosis of Mycobacterium infection. One 
of these tests, the enzyme-linked immunospot (ELIS-
POT) assay, was shown to have a better diagnostic per-
formance when compared with TST (Ewer et al. 2003, 
Fietta et al. 2003, Brock et al. 2004). The ELISPOT assay 
is closely correlated with the exposure of the individual 
to Mycobacterium (Ewer et al. 2003) and shows less inde-
terminate results than TST tests (Dogra et al. 2007).
A peptide-based IGRA test could offer several ad-
vantages, including the precise knowledge of the antigen 
specificity. However, such peptides should be widely 
recognised by the population to be tested. Until recent-
ly, the available tools for searching immunodominant 
epitopes was the direct testing of substantial numbers 
of overlapping peptides or peptide libraries. The iden-
tification of major histocompatibility complex-binding 
motifs allowed the prediction of potential T-cell epitopes 
(Rammensee 1995) and such motifs were found to clus-
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ter in certain protein regions (Meister et al. 1995). The 
TEPITOPE algorithm predicts binding to 25 distinct hu-
man leukocyte antigen (HLA)-DR molecules based on 
quantitative matrices established from HLA-DR bind-
ing assays (Sturniolo et al. 1999, Bian et al. 2003, Iwai 
et al. 2003, Fonseca et al. 2004, 2006, Damico et al. 
2005). This advance lead to the selection of sequences 
enriched for high affinity-binding peptides, those with 
the highest chance of eliciting effective T-cell responses 
against immunogens (Schroers et al. 2002). Additional-
ly, TEPITOPE also allows for the detection of sequences 
predicted to bind to several HLA-DR molecules simul-
taneously, opening the possibility of selecting promiscu-
ous T-cell epitopes. Another advantage of the peptide-
based IGRA test is the ability to test individual peptides, 
allowing for the analysis of peptide-specific T cell re-
sponses as well as peptide pools.
Therefore, to identify the frequently recognised im-
munodominant epitopes of three immunogenic proteins 
of MTB, we used the TEPITOPE algorithm to screen 
GroEL-2 (Shinnick 1987, Fleischmann et al. 2002), 
phosphate-binding protein 1 precursor (PBP-1) (Ander-
sen & Hansen 1989) and 19 kDa antigen (Ashbridge et 
al. 1989), which are proteins that were previously found 
to elicit potentially strong immunological responses 
(Tanghe et al. 1999, Lewthwaite et al. 2001, Mendelson 
et al. 2005, Wilkinson et al. 2009), for multiple HLA-
DR binding sequences, in a group of healthy individu-
als. Synthetic peptides encoding such potential CD4+ T 
cell epitopes were used in IFN-γ  ELISPOT assays with 
peripheral blood mononuclear cells (PBMCs) of TST-
positive and TST-negative Brazilian healthy subjects.
SUBJECTS, MATERIALS AND METHODS
Subjects - The sample comprised 32 Brazilian healthy 
volunteers (donors) selected from students and workers 
from the Advanced Laboratory of Public Health, Oswal-
do Cruz Foundation (Fiocruz), Salvador, state of Bahia, 
Brazil, and the Immunology Laboratory, Heart Institute, 
University of São Paulo (USP), São Paulo, state of São 
Paulo, Brazil. All donors received Bacille Calmette-
Guérin (BCG) vaccination during childhood. The mean 
age of the 32 donors was 32 ± 9 years. They were di-
vided into two groups according to the TST response: 
latent MTB infection (16 subjects, TST-positive) and 
uninfected controls (16 subjects, TST-negative), with a 
mean age of 35 ± 11 years (TST-positive) or 30 ± 7 years 
(TST-negative). The TST was performed according to 
the Mantoux method with PPD, following the manufac-
turer’s instructions (Statens Serum Institute, Denmark). 
TST was considered positive when the induration was ≥ 
10 mm after 48 h of PPD application. All of the individu-
als gave their written informed consent to participate in 
this study, which was approved by the Institutional Re-
view Boards of the School of Medicine, USP (protocol 
250/04) and Fiocruz (protocol 51/2004).
Peptide selection - Sequences of three important an-
tigens expressed by MTB were used: GroEL2 protein, 
accession P9WPE6.1 (Fleischmann et al. 2002), PBP-1, 
accession P9WGU0.1 (Andersen & Hansen 1989) and 
19 kDa antigen, accession S02753 (Ashbridge et al. 
1989). These sequences were screened by TEPITOPE 
and we predicted seven epitopes that were used in the 
ELISPOT assay. The seven peptides were predicted to 
bind to at least 12 out of the 25 HLA-DR molecules in 
the TEPITOPE matrix, as previously described (Bian et 
al. 2003). They correspond to an inner nonamer core se-
lected as the HLA-binding motif with flanking amino 
acids added when possible (e.g., conserved flanking se-
quences) at either or both the N and C-terminal ends, to 
increase the efficiency of in vitro peptide presentation to 
CD4+ T cells (Bian et al. 2003, Fonseca et al. 2006).
Peptide synthesis - Peptides of the MTB proteins 
were synthesised by solid phase technology using 9-flu-
orenylmethoxycarbonyl strategy, with the C-terminal 
carboxyl group in amide form. Peptide purity and quality 
were assessed by reverse-phase high performance liquid 
chromatography and mass spectrometry, as described 
elsewhere (Atherton & Sheppard 1989). The peptides 
were dissolved in dimethyl sulfoxide (DMSO) for stock 
solutions of 25 mg/mL.
PBMC separation - PBMC suspensions were prepared 
from 50 mL heparinised venous blood by density gradient 
centrifugation using Ficoll-Hypaque, 1.077 g/L (Pharma-
cia, Sweden). The cells were washed twice with phosphate-
buffered saline (PBS) (Gibco, UK) and were kept frozen 
at -196ºC in liquid nitrogen in foetal calf serum (FCS) 
containing 10% DMSO (Merck, Germany) until testing. 
After thawing, the PBMCs were suspended in RPMI-1640 
(Gibco), supplemented with 200 mM glutamine, 100 U/
mL penicillin, 100 U/mL streptomycin and 10% FCS, 100 
mM non-essential amino acids and 100 mM pyruvate.
IFN-γ ELISPOT assays - The IFN-γ ELISPOT assay 
was performed as described previously (Sun et al. 2003, 
Fonseca et al. 2005, Zhang et al. 2009, Xie et al. 2010). 
Briefly, cryopreserved PBMCs (105 cells/well) were in-
cubated with 5 μM of each peptide on a 96-well Multi-
Screen ELISPOT plate (Multiscreen MAIPS4510; Milli-
pore, USA) previously coated with 50 μL/well of capture 
anti-human IFN-γ monoclonal antibody (mAb) diluted 
1/1,000 (IgG1/B-B1; Diaclone, France) in PBS (1 μL/mL 
of mAb) at 4ºC overnight. The plates were washed three 
times with PBS. The remaining peptide binding sites 
were blocked with 100 μL RPMI/10% FCS for 2 h at 
37ºC. The medium was removed just before the addition 
of cell suspensions (100 μL) and stimulating agents (100 
μL). The MTB peptides (5 μM) were added to each well 
of the plates. The plates were incubated for 20 h at 37ºC 
in 5% CO
2
. PBMCs incubated with 0.5 μg/mL phytohe-
magglutinin (Sigma, France) or RPMI/10% FCS served 
as the positive and negative controls, respectively. At the 
end of the incubation, the cells were removed from the 
ELISPOT plates by washing nine times: three times with 
PBS, three times with PBS containing 0.05% Tween-20 
(Sigma) and three times again with PBS. Spots were de-
tected after the addition of the second biotinylated anti-
human IFN-γ mAb (B-G1; Diaclone) (100 μL/well, 4 h, 
37ºC in 5% CO
2
), diluted 1/500 in PBS-bovine serum al-
bumin (PBS-BSA) (Gibco) (1 μL/500 μL of biotinylated 
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antibody). The plates were washed three times with PBS, 
followed by streptavidin-alkaline phosphatase conjugate 
(Amersham, France) (100 μL/well, 1 h, 37ºC in 5% CO
2
) 
diluted 1/1000 in PBS-BSA (1 μL/mL of streptavidin-
alkaline phosphatase conjugate), washed three times 
with PBS and incubated with 50 μL/well of chromogen 
substrates 5-bromo-4-chloro-3-indolyl-phosphate tolui-
dine and 4-nitroblue tetrazolium (Sigma), which were 
incubated at room temperature (25ºC) until the appear-
ance of violet spots (~ 30 min). The plates were washed 
with tap water and dried overnight. Antigen-specific T 
cells, expressed as spot forming cells (SFC)/106 PBMCs 
frequencies, were measured using an automated ste-
reomicroscope (KS ELISPOT; Carls Zeiss, Germany). 
The SFC number was calculated after subtracting the 
negative control values (wells with cells in the absence 
of peptide) from the same subject. The positivity cut-
off was ≥ 30 IFN-γ SFC/106 PBMCs, which was above 
the mean ± 3 standard deviation of the highest response 
found among all uninfected control subjects to any pep-
tide (data not shown). The magnitude of response to each 
given peptide or the sum of the SFC of the total peptides 
was calculated as the SFC/106 PBMCs of peptides with 
responses above the positivity cut-off.
Statistical analysis - Statistical analysis was per-
formed using the GraphPad Prism package v.3.0. 
Comparisons of the number of IFN-γ SFC/106 PBMCs 
between the clinical groups were performed with a 
non-parametric one-way ANOVA, Kruskal-Wallis and 
Dunn’s Test. The Mann-Whitney U test was used to cal-
culate the differences between the groups. Values of p < 
0.05 were considered significant.
RESULTS
Three MTB antigenic proteins, GroEL2, PBP-1 and 19 
kDa, were scanned with the TEPITOPE algorithm at a 3% 
threshold. Seven peptide sequences predicted to bind to 
multiple HLA-DR molecules were synthesised (Table I).
Next, we tested if the IFN-γ response to the seven 
peptides could discriminate between TST-positive and 
TST-negative healthy donors. The mean size (± standard 
deviation) of PPD induration detected for TST-negative 
individuals was 0.71 ± 2.02 mm and for TST-positive in-
dividuals was 11.14 ± 4.07 mm. PBMCs from the 16 TST-
positive and 16 TST-negative individuals were tested in 
the presence of each peptide for an IFN-γ ELISPOT assay. 
The T cell responses are shown in Table II. The frequen-
cy of peptide recognition by the TST-positive group was 
significantly higher than the TST-negative group. Eighty-
eight percent (14 out of 16 donors) of TST-positive donors 
recognised at least one peptide and 31% (5 out of 16 do-
nors) had responses to three or more peptides, while in the 
TST-negative group, 31% (5 out of 16 donors) responded to 
any peptides and only 12% (2 out of 16 donors) responded 
to three or more peptides (p = 0.002) (Fig. 1).
Each of the selected peptides induced IFN-γ produc-
tion by PBMCs from at least 31% of the TST-positive 
donors. The frequency of responders to individual pep-
tides ranged from 31% to PBP-1 (118-133), PBP-1 (352-
371) and 19 kDa (127-141) to 56% to GroEL2 (215-229) 
(Fig. 2). In contrast, among TST-negative donors, there 
was no response to GroEL2 (463-477) peptide and the 
most frequently recognised peptides were PBP-1 (351-
365) and PBP-1 (352-371), with 19% of responders.
The magnitude of responses to the peptides (sum of 
IFN-γ SFC of all peptides with positive responses) was 
higher in the TST-positive group than in the TST-nega-
tive group (Fig. 3). The total number of IFN-γ SFC in re-
sponse to MTB peptides was 182 ± 230 SFC/106 PBMCs 
among the TST-positive donors, compared to 36 ± 62 
SFC/106 PBMCs in the TST-negative donors (p = 0.007). 
The magnitude of the responses per individual ranged 
from 0-725 SFC/106 PBMCs among the TST-positive in-
dividuals and 0-170 SFCs/106 PBMCs among the TST-
negative individuals (Table II).
The PBP-1 (351-365) MTB peptide induced the high-
est magnitude of response, 627 SFC/106 PBMCs, followed 
by PBP-1 (352-371), with 446 SFC/106 PBMCs (Fig. 3). 
In the TST-negative group, the highest magnitude of 
response was to PBP-1 (352-371), with 185 SFC/106 PB-
MCs. In addition, a response to GroEL2 (463-477) was 
observed only in the TST-positive group (p = 0.02).
Taking into consideration that all 32 healthy donors 
were subjected to BCG vaccination, the combination of 
TST and positivity at the IFN-γ ELISPOT test raised the 
TABLE I
Sequences of peptides derived from Mycobacterium tuberculosis (MTB)  
sequences selected by TEPITOPE algorithm
Peptide
HLA-DR molecules predicted to bind to peptidea
(%) Sequence
GroEL2 (215-229) 76 DPYILLVSSKVSTVK
GroEL2 (463-477) 60 AEKVRNLPAGHGLNA
PBP-1 (59-75) 84 TLLYPLFNLWGPAFHER
PBP-1 (118-133) 88 KGLMNIALAISAQQVN
PBP-1 (351-365) 64 QVHFQPLPPAVVKLS
PBP-1 (352-371) 84 VHFQPLPPAVVKLSDALIAT
19 kDa (127-141) 48 GSHYKITGTATGVDM
a: 3% threshold; HLA: human leukocyte antigen.
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Fig. 3: magnitude of responses to Mycobacterium tuberculosis pep-
tides. The bars represent the magnitude of response of each peptide 
(overall sum of spots of all individuals with positive responses). Posi-
tive responses > 30 spot forming cells (SFC) interferon (IFN)-γ/106 
peripheral blood mononuclear cells (PBMCs) (p = 0.007, Mann-Whit-
ney U test). TST+: tuberculin skin test-positive; TST-: TST-negative.
Fig. 1: number of Mycobacterium tuberculosis (MTB) peptides recog-
nised by tuberculin skin test (TST)-positive (TST+) and TST-negative 
(TST-) donors. Peripheral blood mononuclear cells (PBMCs) from 16 
TST-positive and 16 TST-negative healthy donors were assayed with 
seven human leukocyte antigen-DR promiscuous peptides derived 
from MTB protein sequences. Each peptide was tested individually 
at concentration of 5 µM and the number of spot forming cells (SFC) 
interferon-γ/106 PBMC were calculated according to the following 
equation: (average spots in duplicate peptide wells - average spots in 
duplicate control wells) x 5. Positive responses were ≥ 30 SFC/106 
PBMC. The columns represent the number of TST-positive and TST-
negative donors tested that were negative or able to show positive re-
sponses in the ELISPOT assay in response to different numbers of 
peptides (p = 0.01, Mann-Whitney U test).
Fig. 2: proportion of tuberculin skin test (TST)-positive (TST+) and 
TST-negative (TST-) donors that recognised selected Mycobacterium 
tuberculosis (MTB) peptides. Peripheral blood mononuclear cells 
(PBMCs) from 16 TST-positive and 16 TST-negative healthy donors 
were tested with seven MTB derived peptides and the spot forming 
cells interferon-γ/106 PBMC were calculated. The columns represent 
the proportion of TST-positive and TST-negative individuals that rec-
ognised at list one peptide (p = 0.001, Mann-Whitney U test).
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overall positivity value from 50% (16/32) to 59% (19/32) 
for recognition of MTB antigens.
DISCUSSION
Our results suggest that the peptides predicted by 
TEPITOPE are able to identify a significant number of indi-
viduals with latent MTB infection. Moreover, in our study, 
the use of these peptides allowed us to identify individuals 
with latent MTB infection not tracked by the TST test.
The TEPITOPE is an algorithm that uses a matrix 
that predicts the binding of 25 HLA-DR molecules. This 
allows the identification of epitopes with high binding 
affinity and the ability to generate a strong T cell re-
sponse. The use of this algorithm can lead to the iden-
tification of a greater number of epitopes, which would 
display a higher sensitivity and specificity for detecting 
MTB, as reported elsewhere (Zhang et al. 2010).
The two methods used in this study to assess latent 
MTB infection, the TST and the IFN-γ ELISPOT, showed 
similar results in 88% of the evaluated individuals who 
were TST-positive. These findings are similar to the pub-
lished data, in which there is a higher correlation of IGRA 
tests and TB when compared to TST and TB (Bartalesi et 
al. 2009, Girardi et al. 2009, Redelman-Sidi & Sepkowitz 
2013). Furthermore, it was possible to identify TST-neg-
ative individuals (31%) who responded to peptides pre-
dicted by TEPITOPE. In this respect, Ewer et al. (2003) 
reported that ELISPOT offers a more accurate approach 
than TST for the identification of individuals who have 
latent TB infection and could improve TB control by more 
precise targeting of preventive treatment. However, pos-
sible antigenic cross-reactions or non-specific responses 
cannot be excluded and should be addressed. The advan-
tage of using the IGRA with seven promiscuous peptides 
is that would ensure larger number of responder individu-
als independent of HLA class II and also a greater range 
or a greater number of recognised peptides.
To date, no fully effective methodology is available 
that can unequivocally differentiate individuals who actu-
ally have latent MTB infection from those who were BCG 
vaccinated or even those that have active MTB infection. 
The most widely and currently used test for the screen-
ing of latent MTB infection remains the TST because it is 
considered a low cost point-of-care-test (Ewer et al. 2003, 
Diel et al. 2007, Soborg et al. 2009). Therefore, it remains 
the method of choice for screening for latent MTB infec-
tion, primarily due to a better cost/benefit ratio when com-
pared to tests based on IGRA (Lewinsohn et al. 2010).
Richeldi et al. (2009) report that immunocompromised 
persons infected with MTB have a high occurrence of 
false-negative results in the TST and, in such cases, they 
recommend to tailor the application of IGRA assays for 
latent MTB infection in different high-risk groups and ad-
vise caution in their use in immunosuppressed patients.
The results of the TST may show false positive results 
in individuals previously immunised with BCG or be-
cause the population of the study has high rates of expo-
sure to MTB (Soborg et al. 2009). Another relevant aspect 
is that 70-80% of individuals with pulmonary TB have a 
diameter of the induration greater than 10 mm by TST 
and this value is reduced in individuals co-infected with 
HIV-1 (Idh et al. 2010). This combination of novel MTB 
CD4+ T-cell epitopes should be tested in a larger cohort 
of individuals with latent TB to confirm its potential to 
discriminate latent MTB infection from no TB infection 
and may be included in ELISPOT-based IFN-γ response 
assays to identify individuals with such conditions.
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